Can these drugs stop COVID-19 pneumonia from turning severe?

NCT ID NCT04581954

First seen Nov 18, 2025 · Last updated Apr 29, 2026 · Updated 19 times

Summary

This study tested two drugs, ruxolitinib and fostamatinib, in hospitalized adults with mild to moderate COVID-19 pneumonia. The goal was to see if either drug could prevent the disease from becoming severe, such as needing a breathing machine. Participants received the drug for 14 days and were followed for 28 days.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for COVID19 are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Imperial College Healthcare NHS Trust

    London, W12 0HS, United Kingdom

  • London North West University Healthcare

    London, HA1 3UJ, United Kingdom

  • Royal Berkshire NHS Foundation Trust

    Reading, RG1 5AN, United Kingdom

  • Sheffield Teaching Hospitals NHS Foundation Trust - Royal Hallamshire Hospital

    Sheffield, S10 2JF, United Kingdom

  • The Leeds Teaching Hospital - St James University Hospitals NHS Trust

    Leeds, LS9 7TF, United Kingdom

Conditions

Explore the condition pages connected to this study.